Disease · MONDO_0001707

cardiac sarcoidosis

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. cardiac sarcoidosis. Diseases, record MONDO_0001707. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0001707

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: cardiac sarcoidosis; Open Targets
Open Targets ID: MONDO_0001707; Open Targets
Other names: heart sarcoidosis, sarcoidosis of heart; Open Targets
Disease Ontology: DOID:13405; Disease Ontology
NCI Thesaurus: C35589; NCI Thesaurus
Highest stage of its drugs: Phase 3, for 2 of its 6 drugs, from ClinicalTrials.gov; Open Targets

Drugs6

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
METHOTREXATE	CHEMBL34259	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
PREDNISONE	CHEMBL635	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
ANAKINRA	CHEMBL1201570	Protein	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
BARICITINIB	CHEMBL2105759	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
NAMILUMAB	CHEMBL1743044	Antibody	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
RILONACEPT	CHEMBL1201830	Protein	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets

Targets7

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
CSF2	Granulocyte-macrophage colony-stimulating factor	1	Granulocyte-macrophage colony-stimulating factor inhibitor	Phase 2	https://conductscience.org/library/genes/1437	Drugs and targets
DHFR	Dihydrofolate reductase	1	Dihydrofolate reductase inhibitor	Phase 3	https://conductscience.org/library/genes/1719	Drugs and targets
IL1B	Interleukin-1 beta	1	Interleukin-1 beta inhibitor	Phase 2	https://conductscience.org/library/genes/3553	Drugs and targets
IL1R1	Interleukin-1 receptor type 1	1	Interleukin-1 receptor antagonist	Phase 2	https://conductscience.org/library/genes/3554	Drugs and targets
JAK1	Tyrosine-protein kinase JAK1	1	Tyrosine-protein kinase JAK1 inhibitor	Phase 2	https://conductscience.org/library/genes/3716	Drugs and targets
JAK2	Tyrosine-protein kinase JAK2	1	Tyrosine-protein kinase JAK2 inhibitor	Phase 2	https://conductscience.org/library/genes/3717	Drugs and targets
NR3C1	Glucocorticoid receptor	1	Glucocorticoid receptor agonist	Phase 3	https://conductscience.org/library/genes/2908	Drugs and targets

Trials5

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT04017936	Interleukin-1 Blockade for Treatment of Cardiac Sarcoidosis	Phase 2	17	2025-08-07	Cardiac Sarcoidosis	ANAKINRA	Its record names the disease	ClinicalTrials.gov
NCT05351554	A Study to Assess the Safety, Tolerability, and Efficacy of Namilumab in Participants With Active Cardiac Sarcoidosis	Phase 2	1	2025-04-17	Sarcoidosis, Cardiac	NAMILUMAB	Its record names the disease	ClinicalTrials.gov
NCT03593759	Cardiac Sarcoidosis Randomized Trial	Phase 3	160		Cardiac Sarcoidosis, Sarcoidosis	METHOTREXATE, PREDNISONE	Its record names the disease	ClinicalTrials.gov
NCT06660732	Rilonacept in Subjects With Cardiac Sarcoidosis	Phase 2	60		Cardiac Sarcoidosis	RILONACEPT	Its record names the disease	ClinicalTrials.gov
NCT06868381	A Trial of Baricitinib in Patients With Cardiac Sarcoidosis	Phase 2	10		Cardiac Sarcoidosis	BARICITINIB	Its record names the disease	ClinicalTrials.gov

Comparisons in its trials2

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Anakinra vs Standard of Care: deaths from any cause	0 of 7	0 of 10	17	NCT04017936	Trial comparisons
Anakinra vs Standard of Care: serious adverse events	1 of 7	0 of 10	17	NCT04017936	Trial comparisons

Papers from its trials3

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
37092332	RESULT	1	PubMed
34749739	DERIVED	1	PubMed
31911261	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0001707

GET https://conductscience.org/api/diseases/v1/MONDO_0001707/drugs

API reference For AI assistants